Afuresertib hydrochloride is an inhibitor of Akt kinase (Kis of 0.08/2/2.6 nM for Akt1/Akt2/Akt3 respectively)

PKCθ:510 nM, PKCβI:430 nM, Akt1:0.08 nM(Ki), Akt3:2.6 nM(Ki), Akt1 E17K mutant:0.2 nM, Akt2:2 nM(Ki), ROCK:100 nM, PKCη:210 nM

Afuresertib-induced p21 expression promotes G1 phase arrest by inducing FOXO activity.?Furthermore, afuresertib significantly enhanced cisplatin-induced cytotoxicity.Afuresertib modulated the expression E2F1 and MYC, which are associated with fibroblast core serum response.?Suggest that afuresertib is a useful anticancer drug for treating patients with MPM[1].

Cell confluence proliferation assay was performed using Incucyte ZOOM Live‐Cell Imaging System.?Briefly, ACC‐MESO‐4 and MSTO‐211H cells were seeded in 12‐well plates (cell density, 1 × 104 cells/well) and were incubated for 24 h at 37°C.?Then, the cells were incubated with 0, 2, 5, or 10 μmol/L afuresertib.?During treatment, cell growth was monitored by recording phase images using the IncuCyte ZOOM Live‐Cell Imaging System (magnification, ×100)[1].